ArticleTranslational cancer research2025
A development and validation of predictive model based on novel immune-related gene-based subtypes for the risk assessment of cutaneous melanoma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cutaneous melanoma (CM) exhibits considerable heterogeneity, and the immune status of patients can serve as a prognostic indicator. The increasing significance of immune-related markers in cancer prognosis provides clinicians with valuable tools for risk stratification and management decisions. The objective of this study was to develop a predictive model for assessing the risk of CM based on novel subtypes delineated according to immune-related genes. Methods: This study included a cohort from The Cancer Genome Atlas (TCGA). Immune-related genes were carefully selected, and a comprehensive analysis was performed to characterize the molecular alterations and clinical implications linked to these genes. From this, an immune-related risk scoring system aimed at predicting the survival outcomes of patients diagnosed with CM was developed. Results: In this study, using an unsupervised consensus clustering algorithm, the study identified two subtypes-Cluster 1 (C1) and Cluster 2 (C2)-within the TCGA melanoma (MEL) cohort based on 1,959 immune-related genes. Survival analysis indicated that C1 was linked to poorer overall survival (OS) as compared to C2. We found significant correlations between these subtypes and clinical variables including tumor-node-metastasis (TNM) classification, new tumor events, and radiation therapy. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed that 161 genes upregulated in C1 were associated with tyrosine metabolism, melanogenesis, and the p53 signaling pathway, while downregulated genes in C1 were linked to hematopoietic cell lineage, cytokine-cytokine receptor interactions, and cell adhesion molecules. Immune-related genes in CM were optimized and assessed using univariate Cox regression and a protein-protein interaction (PPI) network, with 20 genes being identified, including Conclusions: CM was divided into two subtypes based on immune gene expression, with the C1 subtype associated with poor prognosis. A prognostic risk model was developed using these classifications to predict patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.